大腸がん
レジメン名をクリックするとレジメンの投与スケジュールが閲覧できます。
最終更新日:2023年10月2日
- CRC-101: mFOLFOX6
- CRC-102: FOLFIRI
- CRC-103: sLV5FU2
- CRC-104: Bv+mFOLFOX6
- CRC-105: Bv+mFOLFIRI
- CRC-106: Bv+sLV5FU2
- CRC-107: weekly CPT-11
- CRC-109: UFT/LV
- CRC-110: Capecitbine単剤
- CRC-111: S-1単剤
- CRC-112: Cetuximab単剤(weekly)
- CRC-113: Cmab+CPT-11(Cmab:weekly)
- CRC-114: Cmab+FOLFIRI(weekly)
- CRC-115: CapeOX(XELOX)
- CRC-116: Bv+CapeOX(Bv+XELOX)
- CRC-118: Panitumumab単剤
- CRC-119: Pmab+mFOLFOX6
- CRC-120: Pmab+FOLFIRI
- CRC-121: Cmab+mFOLFOX6(Cmab:weekly)
- CRC-122: IRIS
- CRC-124: Pmab+CPT-11
- CRC-125: adj CapeOX
- CRC-126: adj mFOLFOX6
- CRC-127: CPT-11単剤(biweekly)
- CRC-129: Cmab+mFOLFOX6(Cmab:biweekly)
- CRC-132: Bv+Cape
- CRC-133: Bv+SOX
- CRC-134: Cmab+CPT-11(Cmab:biweekly)
- CRC-135: Bv+S-1
- CRC-138: RAM+FOLFIRI
- CRC-139: FOLFOXIRI±Bv
- CRC-140: SIRB
- CRC-141: Aflibercept+FOLFIRI
- CRC-142: Bv+UFT/LV
- CRC-143: Bv+IRI
- CRC-144: CapeIRI±Bv(XELIRI±Bv)
- CRC-145: Bv+IRIS
- CRC-146: Nivolumab単剤(MSI-High大腸がん)
- CRC-147: Bv+TAS102
- CRC-149:Cetuximab+FOLFIRI(biweekly)
- CRC-150:BEACON triplet((Cmab+ENCO+BINI)Cmab-biweekly)
- CRC-150:BEACON triplet((Cmab+ENCO+BINI)Cmab-weekly)
- CRC-151:BEACON doublet((Cmab+ENCO)Cmab-biweekly)
- CRC-151:BEACON doublet((Cmab+ENCO)Cmab-weekly)
- CRC-152:mFOLFOXIRI±Bv
- CRC-153:Cetuximab単剤(biweekly)
- CRC-154:Cmab+mFOLFOXiIRI
- CRC-155:pembrolizumab単剤(MSI-High)
- CRC-157:PER+HER